2020年7月25日 · PI3K signaling along with phosphorylation of its downstream targets was reduced upon Sirt6 downregulation. Xenograft models subjected to either OSS_128167 treatment or Sirt6-knockdown showed suppressed tumor growth and lower Ki-67 level.

2021年6月9日 · 文章： Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling. 分子： Sirtuin 6 (Sirt6)是一种高度保守的ADP-核糖化酶和NAD+依赖的脱酰酶，参与广泛的细胞过程。 该酶涉及细胞抗应激、基因组稳定性、老化和能量稳态。 编码蛋白定位于细胞核，具有ADP-核糖体转移酶和组蛋白去乙酰化酶活性，在DNA修复、端粒染色质维持、炎症、脂质和糖代谢等方面发挥作用。 这种分子在致癌过程中具有相互 …

In vivo experiments showed that overexpression of SIRT6 promoted the inhibitory effect of radiation on the growth of NSCLC xenograft tumors in nude mice. SIRT6 can promote the radiosensitivity of NSCLC and inhibit the development of tumor by down-regulating the activity of PI3K/Akt/mTOR signaling pathway.

SIRT6-sensitive cancer cells bear mutations that activate phosphatidylinositol-3-kinase (PI3K) signaling, and overexpression of SIRT6 reduces growth, progression, and grade of breast cancer in a mouse model with PI3K activation.

2017年2月21日 · SIRT6 overexpression suppresses PI3K signaling at the transcriptional level and antagonizes tumor sphere formation independent of its histone deacetylase activity. Our data identify SIRT6 as a putative molecular target that hinders …

2022年9月15日 · Here, we show that SIRT6, a chromatin-associated deacetylase indirectly regulates glucocorticoid-induced muscle wasting by modulating IGF/PI3K/AKT signaling. Our results show that SIRT6...

结论 去乙酰化酶SIRT6 能够通过下调PI3K-AKT 通路从而抑制肾癌细胞的增殖、迁 移，可能成为药物治疗的潜在新靶点。 关键词 SIRT6;肾癌细胞;ACHN;786-O;OSS_128167;迁移; 增殖 中图分类号 R 34 文献标志码A 文章编号1000 －1492(2021)12 －1914 －06 doi:10．19405/j． cnki． issn1000 －1492．2021．12．013.

2019年11月13日 · OSS_128167, a novel targeted inhibitor of Sirt6, exerted excellent anti-lymphoma effects via activating PI3K/Akt/mTOR signaling. In addition, blockade of Sirt6 expression enhanced the sensitivity of DLBCL cells to chemotherapeutic agents.

2021年5月25日 · SIRT6 can promote the radiosensitivity of NSCLC and inhibit the development of tumor by down-regulating the activity of PI3K/Akt/mTOR signaling pathway.

OSS_128167 是一种新型的 Sirt6 靶向抑制剂，通过激活 PI3K/Akt/mTOR 信号传导发挥出色的抗淋巴瘤作用。 此外，Sirt6 表达的阻断增强了 DLBCL 细胞对化疗药物的敏感性。